Sana Biotechnology Inc (SANA)

Mar 28, 2025, 10:05 AM EDT - 6 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

Mar 27, 2025, 1:34 PM EDT - 6 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

Mar 27, 2025, 5:45 AM EDT - 7 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA

Mar 24, 2025, 11:45 PM EDT - 9 days ago

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

Mar 17, 2025, 4:05 PM EDT - 16 days ago

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 4:05 PM EST - 5 weeks ago

Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference

Jan 8, 2025, 4:05 PM EST - 3 months ago

Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 10:30 AM EST - 3 months ago

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Jan 8, 2025, 9:27 AM EST - 3 months ago

Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why

Jan 8, 2025, 7:25 AM EST - 3 months ago

This Biotech Stock Just Soared 240%. Why It Can Go Higher.

Jan 7, 2025, 4:05 PM EST - 3 months ago

Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Dec 4, 2024, 3:36 PM EST - 4 months ago

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Nov 25, 2024, 4:05 PM EST - 4 months ago

Sana Biotechnology to Present at December 2024 Investor Conferences

Nov 19, 2024, 5:31 PM EST - 4 months ago

Sana Biotechnology: The Story Becomes Murkier

Nov 8, 2024, 9:00 AM EST - 5 months ago

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

Nov 4, 2024, 4:30 PM EST - 5 months ago

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

Sep 30, 2024, 4:05 PM EDT - 6 months ago

Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference

Aug 29, 2024, 4:05 PM EDT - 7 months ago

Sana Biotechnology to Present at September 2024 Investor Conferences

Aug 26, 2024, 4:05 PM EDT - 7 months ago

Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

Aug 2, 2024, 7:12 PM EDT - 8 months ago

Sana Biotechnology cuts the ribbon at new manufacturing facility near Seattle

May 6, 2024, 4:05 PM EDT - 11 months ago

Sana Biotechnology to Present at May and June 2024 Investor Conferences

Apr 21, 2024, 9:02 PM EDT - 1 year ago

Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX

RXRX VKTX

Feb 29, 2024, 4:05 PM EST - 1 year ago

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 28, 2024, 4:05 PM EST - 1 year ago

Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference

Feb 13, 2024, 4:05 PM EST - 1 year ago

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

Feb 12, 2024, 4:05 PM EST - 1 year ago

Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 8, 2024, 1:22 AM EST - 1 year ago

Sana Biotechnology Announces Pricing of Upsized Public Offering

Feb 7, 2024, 4:01 PM EST - 1 year ago

Sana Biotechnology Announces Proposed Public Offering of Common Stock

Jan 17, 2024, 2:00 PM EST - 1 year ago

JD Henning Cautious About 2024, An Unusual Year For Market Considerations

BOIL CURE DIA MJ NVDA QQQ SPY

Jan 5, 2024, 3:13 PM EST - 1 year ago

Sana Biotechnology: SC291 Moving Forward Beyond Hematological Malignancies

Jan 5, 2024, 9:00 AM EST - 1 year ago

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

Jan 3, 2024, 4:05 PM EST - 1 year ago

Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 9:00 AM EST - 1 year ago

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

Dec 1, 2023, 4:05 PM EST - 1 year ago

Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System

Nov 21, 2023, 9:00 AM EST - 1 year ago

Sana Biotechnology to Present at November and December 2023 Investor Conferences

Nov 17, 2023, 9:00 AM EST - 1 year ago

Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes